CH609154A5 - Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals - Google Patents

Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals

Info

Publication number: CH609154A5
Authority: CH; Switzerland
Prior art keywords: group; mmol; arg; substrate; substrates
Prior art date: 1974-07-02

Application number

CH921074A

Other languages

German (de)

English (en)

Inventor

Lars Gundro Svendsen

Original Assignee

Pentapharm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-07-02

Filing date

1974-07-02

Publication date

1979-02-15

1974-07-02 Application filed by Pentapharm Ag filed Critical Pentapharm Ag

1974-07-02 Priority to CH921074A priority Critical patent/CH609154A5/de

1975-06-23 Priority to DE2527932A priority patent/DE2527932C2/de

1975-06-24 Priority to ZA00754019A priority patent/ZA754019B/xx

1975-06-24 Priority to IL47554A priority patent/IL47554A/xx

1975-06-30 Priority to DD186968A priority patent/DD120715A5/xx

1975-06-30 Priority to US05/592,023 priority patent/US4016042A/en

1975-06-30 Priority to NO752386A priority patent/NO147212C/no

1975-06-30 Priority to IT24942/75A priority patent/IT1039558B/it

1975-06-30 Priority to CA230,464A priority patent/CA1049506A/fr

1975-07-01 Priority to NLAANVRAGE7507802,A priority patent/NL188354C/xx

1975-07-01 Priority to AU82631/75A priority patent/AU504338B2/en

1975-07-01 Priority to AT505675A priority patent/AT345475B/de

1975-07-01 Priority to SE7507545A priority patent/SE424635B/xx

1975-07-02 Priority to JP8175475A priority patent/JPS5622280B2/ja

1975-07-02 Priority to FR7520756A priority patent/FR2279106A1/fr

1975-07-02 Priority to BE157901A priority patent/BE830911A/fr

1975-07-02 Priority to GB27819/75A priority patent/GB1520261A/en

1979-02-15 Publication of CH609154A5 publication Critical patent/CH609154A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 41
210000001124 body fluid Anatomy 0.000 title claims abstract description 12
239000010839 body fluid Substances 0.000 title claims abstract description 12
108091005804 Peptidases Proteins 0.000 title claims abstract description 11
102000035195 Peptidases Human genes 0.000 title claims abstract description 11
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 title claims abstract description 11
241000124008 Mammalia Species 0.000 title claims abstract description 6
239000000758 substrate Substances 0.000 claims abstract description 80
-1 sulphonyl group Chemical group 0.000 claims abstract description 38
108090000790 Enzymes Proteins 0.000 claims abstract description 36
102000004190 Enzymes Human genes 0.000 claims abstract description 36
229940088598 enzyme Drugs 0.000 claims abstract description 36
108090000113 Plasma Kallikrein Proteins 0.000 claims abstract description 30
102000003827 Plasma Kallikrein Human genes 0.000 claims abstract description 26
238000003776 cleavage reaction Methods 0.000 claims abstract description 11
230000007017 scission Effects 0.000 claims abstract description 11
125000002252 acyl group Chemical group 0.000 claims abstract description 7
230000003301 hydrolyzing effect Effects 0.000 claims abstract description 7
125000001424 substituent group Chemical group 0.000 claims abstract description 4
125000002233 tyrosyl group Chemical group 0.000 claims abstract description 4
125000000405 phenylalanyl group Chemical group 0.000 claims abstract description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 40
238000006243 chemical reaction Methods 0.000 claims description 18
150000001408 amides Chemical class 0.000 claims description 14
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
150000002148 esters Chemical class 0.000 claims description 10
239000006225 natural substrate Substances 0.000 claims description 10
210000002381 plasma Anatomy 0.000 claims description 10
108090000190 Thrombin Proteins 0.000 claims description 9
229960004072 thrombin Drugs 0.000 claims description 9
108010088842 Fibrinolysin Proteins 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
230000003024 amidolytic effect Effects 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
230000000058 esterolytic effect Effects 0.000 claims description 8
229940012957 plasmin Drugs 0.000 claims description 8
108090000631 Trypsin Proteins 0.000 claims description 7
102000004142 Trypsin Human genes 0.000 claims description 7
238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 7
238000005259 measurement Methods 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
230000035939 shock Effects 0.000 claims description 7
239000012588 trypsin Substances 0.000 claims description 7
102000001399 Kallikrein Human genes 0.000 claims description 6
108060005987 Kallikrein Proteins 0.000 claims description 6
230000008033 biological extinction Effects 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
230000007071 enzymatic hydrolysis Effects 0.000 claims description 6
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
125000004103 aminoalkyl group Chemical group 0.000 claims description 5
239000004475 Arginine Substances 0.000 claims description 4
101800004538 Bradykinin Proteins 0.000 claims description 4
239000004215 Carbon black (E152) Substances 0.000 claims description 4
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 4
108010077861 Kininogens Proteins 0.000 claims description 4
102000010631 Kininogens Human genes 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
239000013060 biological fluid Substances 0.000 claims description 4
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 4
238000006555 catalytic reaction Methods 0.000 claims description 4
229930195733 hydrocarbon Natural products 0.000 claims description 4
238000002798 spectrophotometry method Methods 0.000 claims description 4
229960001322 trypsin Drugs 0.000 claims description 4
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
230000002255 enzymatic effect Effects 0.000 claims description 3
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
108010049003 Fibrinogen Proteins 0.000 claims description 2
102000008946 Fibrinogen Human genes 0.000 claims description 2
229940127379 Kallikrein Inhibitors Drugs 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
239000012190 activator Substances 0.000 claims description 2
150000005840 aryl radicals Chemical class 0.000 claims description 2
230000023555 blood coagulation Effects 0.000 claims description 2
229940012952 fibrinogen Drugs 0.000 claims description 2
230000004992 fission Effects 0.000 claims description 2
238000011835 investigation Methods 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000005375 photometry Methods 0.000 claims description 2
230000002829 reductive effect Effects 0.000 claims description 2
102100035792 Kininogen-1 Human genes 0.000 claims 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 137
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 107
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 75
150000001875 compounds Chemical class 0.000 description 59
238000000921 elemental analysis Methods 0.000 description 46
239000000243 solution Substances 0.000 description 46
238000002523 gelfiltration Methods 0.000 description 45
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 40
150000001413 amino acids Chemical class 0.000 description 38
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 33
238000001816 cooling Methods 0.000 description 30
238000000746 purification Methods 0.000 description 28
239000000047 product Substances 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 23
238000004458 analytical method Methods 0.000 description 22
239000000126 substance Substances 0.000 description 22
239000000460 chlorine Substances 0.000 description 20
229920005654 Sephadex Polymers 0.000 description 19
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 18
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 18
239000012507 Sephadex™ Substances 0.000 description 18
239000000843 powder Substances 0.000 description 18
229960000583 acetic acid Drugs 0.000 description 14
239000007795 chemical reaction product Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000002904 solvent Substances 0.000 description 9
230000007717 exclusion Effects 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
239000012043 crude product Substances 0.000 description 6
YQDHCCVUYCIGSW-LBPRGKRZSA-N ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate Chemical group NC(=N)NCCC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC=C1 YQDHCCVUYCIGSW-LBPRGKRZSA-N 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 4
JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000010276 construction Methods 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
GFNKTLQTQSALEJ-UHFFFAOYSA-N 1-isocyanato-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(N=C=O)C=C1 GFNKTLQTQSALEJ-UHFFFAOYSA-N 0.000 description 2
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
102400000967 Bradykinin Human genes 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
GYFYEPQCKDJYCF-UHFFFAOYSA-N (4-nitrophenyl) 3-phenylpropanoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)CCC1=CC=CC=C1 GYFYEPQCKDJYCF-UHFFFAOYSA-N 0.000 description 1
DOXAGUPGJPEQFP-UHFFFAOYSA-N (4-nitrophenyl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 DOXAGUPGJPEQFP-UHFFFAOYSA-N 0.000 description 1
UCQFTYKBLBJWIO-UHFFFAOYSA-N (4-nitrophenyl) cyclohexanecarboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)C1CCCCC1 UCQFTYKBLBJWIO-UHFFFAOYSA-N 0.000 description 1
GGIDEJQGAZSTES-UHFFFAOYSA-N (4-nitrophenyl) octanoate Chemical compound CCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 GGIDEJQGAZSTES-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
SFKZPTYRENGBTJ-UHFFFAOYSA-N 4-methoxynaphthalen-2-amine Chemical compound C1=CC=C2C(OC)=CC(N)=CC2=C1 SFKZPTYRENGBTJ-UHFFFAOYSA-N 0.000 description 1
FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010056740 Genital discharge Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
229940064734 aminobenzoate Drugs 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000005018 casein Substances 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
238000007257 deesterification reaction Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical class OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000004992 toluidines Chemical class 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
- C12Q2337/10—Anilides
- C12Q2337/12—Para-Nitroanilides p-NA

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Peptides Or Proteins (AREA)

CH921074A 1974-07-02 1974-07-02 Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals CH609154A5 (en)

Priority Applications (17)

Application Number	Priority Date	Filing Date	Title
CH921074A CH609154A5 (en)	1974-07-02	1974-07-02	Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals
DE2527932A DE2527932C2 (de)	1974-07-02	1975-06-23	Säureadditionssalze von Tripeptidderivaten und deren Verwendung als Substrate zur Bestimmung von Plasmakallikrein
ZA00754019A ZA754019B (en)	1974-07-02	1975-06-24	A substrate for the quantitative determination of enzymes
IL47554A IL47554A (en)	1974-07-02	1975-06-24	Substrate for the quantitative determination of proteolytic enzymes of class e.c.3.4.4.
DD186968A DD120715A5 (fr)	1974-07-02	1975-06-30
US05/592,023 US4016042A (en)	1974-07-02	1975-06-30	Substrate for the quantitative determination of enzymes
NO752386A NO147212C (no)	1974-07-02	1975-06-30	Kormogent h.h.v. fluorescerende tripeptid for kvantitativ bestemmelse av proteolytiske enzymer
IT24942/75A IT1039558B (it)	1974-07-02	1975-06-30	Substrato cromogend o fluorescente in particolare per la determinazione quantitativia di enzimi
CA230,464A CA1049506A (fr)	1974-07-02	1975-06-30	Substrat forme de tripeptides pour le dosage des enzymes
NLAANVRAGE7507802,A NL188354C (nl)	1974-07-02	1975-07-01	Werkwijze voor de bereiding van een substraat voor de kwantitatieve bepaling van plasmakallikreine en werkwijze voor het kwantitatief bepalen van plasmakallikreine.
AU82631/75A AU504338B2 (en)	1974-07-02	1975-07-01	Peptide substrate for measuring enzymes
AT505675A AT345475B (de)	1974-07-02	1975-07-01	Substrat
SE7507545A SE424635B (sv)	1974-07-02	1975-07-01	Tripeptidderivat for kvantitativ bestemning av proteolytiska enzymer samt anvendning av nemnda tripeptidderivat
JP8175475A JPS5622280B2 (fr)	1974-07-02	1975-07-02
FR7520756A FR2279106A1 (fr)	1974-07-02	1975-07-02	Substrat convenant notamment comme reactif de dosage enzymatique
BE157901A BE830911A (fr)	1974-07-02	1975-07-02	Substrat convenant notamment comme reactif de dosage enzymatique
GB27819/75A GB1520261A (en)	1974-07-02	1975-07-02	Tripeptides containing proline and the use thereof in the quantitative determination of enzymes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH921074A CH609154A5 (en)	1974-07-02	1974-07-02	Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals

Publications (1)

Publication Number	Publication Date
CH609154A5 true CH609154A5 (en)	1979-02-15

Family

ID=4349552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH921074A CH609154A5 (en)	1974-07-02	1974-07-02	Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals

Country Status (3)

Country	Link
BE (1)	BE830911A (fr)
CH (1)	CH609154A5 (fr)
ZA (1)	ZA754019B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395401A (en)	1981-09-09	1983-07-26	Smithkline Beckman Corporation	Renally active dipeptides
CA3002899C (fr)	2015-10-26	2023-01-24	Technip France	Procede de production d'un ecoulement de produit hydrocarbure a partir d'un ecoulement d'alimentation hydrocarbone gazeux et installation associee

1974
- 1974-07-02 CH CH921074A patent/CH609154A5/de not_active IP Right Cessation
1975
- 1975-06-24 ZA ZA00754019A patent/ZA754019B/xx unknown
- 1975-07-02 BE BE157901A patent/BE830911A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
BE830911A (fr)	1975-11-03
ZA754019B (en)	1976-05-26

Legal Events

Date	Code	Title	Description
1993-03-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE2527932C2 (de)	1983-04-21	Säureadditionssalze von Tripeptidderivaten und deren Verwendung als Substrate zur Bestimmung von Plasmakallikrein
DE2661080C2 (fr)	1990-03-22
DE2322115A1 (de)	1973-11-22	Substrate mit hoher empfindlichkeit fuer trypsin und andere proteolytische enzyme
DE2552570C3 (de)	1983-11-17	Tri- und Tetrapeptide und deren Verwendung zur Bestimmung von Serinproteasen
EP0110306B1 (fr)	1990-04-04	Composés chromogènes, leur procédé d'obtention et leur emploi
DE2724211C2 (de)	1987-03-05	Tripeptidderivate und deren Verwendung
EP0034122B1 (fr)	1983-09-21	Dérivés de tripeptides et leur utilisation dans la détermination d'enzymes
DE2322116B2 (de)	1980-01-10	Tri- und Tetrapeptide und deren Verwendung zur Bestimmung von Peptid-Peptidohydrolasen
EP0025190B1 (fr)	1984-06-13	Composés chromogènes et leur utilisation en tant que substrats enzymatiques
DD142550A5 (de)	1980-07-02	Diagnostisches mittel
CH622285A5 (fr)	1981-03-31
DE2753653A1 (de)	1978-06-08	Tetrapeptide, verfahren zu ihrer herstellung sowie ihre verwendung zur bestimmung von serinproteasen
EP0019589B1 (fr)	1983-11-09	Dérivés de tripeptides et leur utilisation dans un procédé pour déterminer les enzymes
DE3875359T2 (de)	1993-04-29	Dipeptide, verfahren zur herstellung und verwendung in der bestimmung von proteasen.
CH609154A5 (en)	1979-02-15	Method for the quantitative determination of proteolytic enzymes in body fluids from humans and mammals
US4162941A (en)	1979-07-31	Method for determining a proteolytic enzyme
EP0258784B1 (fr)	1992-12-09	Composés chromogènes, leur procédé de préparation et leur emploi
CH641761A5 (en)	1984-03-15	Tripeptide derivatives for the determination of plasminogen activators and trypsin
DE69017903T2 (de)	1995-11-02	Peptidsubstrate zur identifikation von faktor xa.
JPS62122599A (ja)	1987-06-03	酵素活性測定用ペプチド誘導体及びその使用法
DE68928304T2 (de)	1998-02-05	Substrate für die Bestimmung von Enzymaktivität und Zwischenverbindungen für die Synthese dieser Substrate sowie Prozess der Herstellung der Zwischenverbindungen